No mutation, tumour initiation

Daniela Senft

DOI: https://doi.org/10.1038/s41568-024-00711-9

IF: 78.5

2024-05-30

Nature Reviews Cancer

Abstract:Parreno et al. provide evidence for epigenetically initiated cancers in Drosophila and show that cancer develops after transient loss of Polycomb group proteins in the absence of recurrent mutations.

oncology

What problem does this paper attempt to address?

Transient loss of Polycomb components induces an epigenetic cancer fate

V. Parreno,V. Loubiere,B. Schuettengruber,L. Fritsch,C. C. Rawal,M. Erokhin,B. Győrffy,D. Normanno,M. Di Stefano,J. Moreaux,N. L. Butova,I. Chiolo,D. Chetverina,A.-M. Martinez,G. Cavalli

DOI: https://doi.org/10.1038/s41586-024-07328-w

IF: 64.8

2024-04-25

Nature

Abstract:Although cancer initiation and progression are generally associated with the accumulation of somatic mutations 1,2 , substantial epigenomic alterations underlie many aspects of tumorigenesis and cancer susceptibility 3,4,5,6 , suggesting that genetic mechanisms might not be the only drivers of malignant transformation 7 . However, whether purely non-genetic mechanisms are sufficient to initiate tumorigenesis irrespective of mutations has been unknown. Here, we show that a transient perturbation of transcriptional silencing mediated by Polycomb group proteins is sufficient to induce an irreversible switch to a cancer cell fate in Drosophila . This is linked to the irreversible derepression of genes that can drive tumorigenesis, including members of the JAK–STAT signalling pathway and zfh1 , the fly homologue of the ZEB1 oncogene, whose aberrant activation is required for Polycomb perturbation-induced tumorigenesis. These data show that a reversible depletion of Polycomb proteins can induce cancer in the absence of driver mutations, suggesting that tumours can emerge through epigenetic dysregulation leading to inheritance of altered cell fates.

multidisciplinary sciences
Loss of the Polycomb group gene polyhomeotic induces non-autonomous cell overproliferation.

Siqian Feng,Jianhua Huang,Jian Wang

DOI: https://doi.org/10.1038/embor.2010.188

IF: 9.071

2011-01-01

EMBO Reports

Abstract:Polycomb group (PcG) proteins are conserved epigenetic regulators that are linked to cancer in humans. However, little is known about how they control cell proliferation. Here, we report that mutant clones of the PcG gene polyhomeotic (ph) form unique single-cell-layer cavities that secrete three JAK/STAT pathway ligands, which in turn act redundantly to stimulate overproliferation of surrounding wild-type cells. Notably, different ph alleles cause different phenotypes at the cellular level. Although the ph-null allele induces non-autonomous overgrowth, an allele encoding truncated Ph induces both autonomous and non-autonomous overgrowth. We propose that PcG misregulation promotes tumorigenesis through several cellular mechanisms.
Evidence of epigenetic oncogenesis: a turning point in cancer research

Jean-Pascal Capp,Benoît Aliaga,Vera Pancaldi

2024-11-21

Abstract:In cancer research, the term epigenetics was used in the 1970s in its modern sense encompassing non-genetic events modifying the chromatin state, mainly to oppose the emerging oncogene paradigm. However, starting from the establishment of this prominent concept, the importance of these epigenetic phenomena in cancer rarely led to questioning the causal role of genetic alterations. Only in the last 10 years, the accumulation of problematic data, better experimental technologies, and some ambitious models pushed the idea that epigenetics could be at least as important as genetics in early oncogenesis. Until this year, a direct demonstration of epigenetic oncogenesis was still lacking. Now Parreno, Cavalli and colleagues, using a refined experimental model in the fruit fly Drosophila melanogaster, enforced the initiation of tumours solely by imposing a transient loss of Polycomb repression, leading to a purely epigenetic oncogenesis phenomenon. Despite a few caveats that we discuss, this pioneering work represents a major breakpoint in cancer research that leads us to consider the theoretical and conceptual implications on oncogenesis and to search for links between this artificial experimental model and naturally occurring processes, while revisiting cancer theories that were previously proposed as alternatives to the oncogene-centered paradigm.

Genomics
Tumours form without genetic mutations

Anne-Kathrin Classen

DOI: https://doi.org/10.1038/d41586-024-01019-2

IF: 64.8

2024-04-25

Nature

Abstract:Researchers find that brief and reversible inhibition of a gene-silencing mechanism leads to irreversible tumour formation in fruit flies, challenging the idea that cancer is caused only by permanent changes to DNA. Temporarily disrupting epigenetic silencing causes flies to grow tumours.

multidisciplinary sciences
Sustained inactivation of the Polycomb PRC1 complex induces DNA repair defects and genomic instability in epigenetic tumors

Chetan C. Rawal,Vincent Loubiere,Nadejda L. Butova,Juliette Gracia,Victoria Parreno,Chiara Merigliano,Anne-Marie Martinez,Giacomo Cavalli,Irene Chiolo

DOI: https://doi.org/10.1007/s00418-024-02302-z

2024-06-20

Histochemistry and Cell Biology

Abstract:Cancer initiation and progression are typically associated with the accumulation of driver mutations and genomic instability. However, recent studies demonstrated that cancer can also be driven purely by epigenetic alterations, without driver mutations. Specifically, a 24-h transient downregulation of polyhomeotic ( ph -KD), a core component of the Polycomb complex PRC1, is sufficient to induce epigenetically initiated cancers (EICs) in Drosophila , which are proficient in DNA repair and characterized by a stable genome. Whether genomic instability eventually occurs when PRC1 downregulation is performed for extended periods of time remains unclear. Here, we show that prolonged depletion of PH, which mimics cancer initiating events, results in broad dysregulation of DNA replication and repair genes, along with the accumulation of DNA breaks, defective repair, and widespread genomic instability in the cancer tissue. A broad misregulation of H2AK118 ubiquitylation and to a lesser extent of H3K27 trimethylation also occurs and might contribute to these phenotypes. Together, this study supports a model where DNA repair and replication defects accumulate during the tumorigenic transformation epigenetically induced by PRC1 loss, resulting in genomic instability and cancer progression.

cell biology,microscopy
Evolution and genomic signatures of spontaneous somatic mutation in Drosophila intestinal stem cells

Nick Riddiford,Katarzyna Siudeja,Marius van den Beek,Benjamin Boumard,Allison J. Bardin

DOI: https://doi.org/10.1101/gr.268441.120

IF: 9.438

2021-06-24

Genome Research

Abstract:Spontaneous mutations can alter tissue dynamics and lead to cancer initiation. Although large-scale sequencing projects have illuminated processes that influence somatic mutation and subsequent tumor evolution, the mutational dynamics operating in the very early stages of cancer development are currently not well understood. To explore mutational processes in the early stages of cancer evolution, we exploited neoplasia arising spontaneously in the Drosophila intestine. Analysing whole-genome sequencing data with a dedicated bioinformatic pipeline, we found neoplasia formation to be driven largely through the inactivation of Notch by structural variants, many of which involve highly complex genomic rearrangements. The genome-wide mutational burden in neoplasia was found to be similar to that of several human cancers. Finally, we identified genomic features associated with spontaneous mutation, and defined the evolutionary dynamics and mutational landscape operating within intestinal neoplasia over the short lifespan of the adult fly. Our findings provide unique insight into mutational dynamics operating over a short timescale in the genetic model system, Drosophila melanogaster .

genetics & heredity,biochemistry & molecular biology,biotechnology & applied microbiology
Abstract LB-237: Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes Duringoncogenic Transformation

Boris G. Wilson,Xi Wang,Xiaohua Shen,Elizabeth S. McKenna,Madeleine E. Lemieux,Yoon-Jae Cho,Edward C. Koelhoffer,Scott L. Pomeroy,Stuart H. Orkin,Charles W.M Roberts

DOI: https://doi.org/10.1158/1538-7445.am2011-lb-237

IF: 11.2

2011-01-01

Cancer Research

Abstract:Abstract While epigenetic alterations are widely present in cancers, in the context of genomic instability it has been difficult to determine the degree to which epigenetic alterations serve as primary drivers of tumorigenesis. Cancers initiated by mutation of the SNF5 chromatin remodeling subunit, despite being highly aggressive and lethal, are diploid and genomically stable, making them an ideal model for this purpose. SNF5 is a core subunit of the SWI/SNF chromatin complex and is mutated in the large majority of malignant rhabdoid tumors (MRT), highly lethal cancers that occur in kidney, brain, and soft tissues of young children. Inactivating mutations in SNF5 have also recently been found to occur in a variety of other cancers and mutations in other SWI/SNF subunits occur frequently in ovarian, endometrial, renal, and lung cancers. Given our findings of genomic stability, we hypothesize that the consequences of SNF5 loss are fundamentally epigenetic in nature; that characterization of the epigenetic changes present in our model systems, rather than in cancers with genome instability, will identify those epigenetic alterations capable of driving oncogenic transformation; and lastly that cancers carrying mutations in the SWI/SNF complex can be effectively treated with epigenetically targeted therapies. Analysis of Drosophila mutants suggests that Polycomb and SWI/SNF complexes can serve antagonistic developmental roles. However, the relevance of this relationship to human disease is unclear. Here we have investigated functional relationships between these epigenetic regulators in oncogenic transformation. Mechanistically, we show that loss of the SNF5 tumor suppressor leads to elevated expression of the Polycomb gene EZH2 and that Polycomb targets are broadly H3K27-trimethylated and repressed in SNF5-deficient fibroblasts and cancers. Further, we show antagonism between SNF5 and EZH2 in the regulation of stem cell-associated programs and that Snf5 loss activates those programs. Finally, using conditional mouse models, we show that inactivation of Ezh2 blocks tumor formation driven by Snf5 loss. Collectively, we demonstrate that the rapid onset of tumor formation following SNF5 loss arises due to imbalanced epigenetic antagonism between the SWI/SNF complex and the Polycomb complex PRC2. Our work reveals essential roles for epigenetic modifications during tumor formation and demonstrates that inactivation of EZH2 can have therapeutic efficacy against cancer in vivo. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr LB-237. doi:10.1158/1538-7445.AM2011-LB-237
Dysregulation of epigenetically induced cancers

Henry Ertl

DOI: https://doi.org/10.1038/s41576-024-00742-w

IF: 59.581

2024-05-14

Nature Reviews Genetics

Abstract:A study in Nature finds that transient perturbation of the Polycomb complex and target epigenome can irreversibly induce cancer cell fates.

genetics & heredity
Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes During Oncogenic Transformation

Boris G Wilson,Xi Wang,Xiaohua Shen,Elizabeth S McKenna,Madeleine E Lemieux,Yoon-Jae Cho,Edward C Koellhoffer,Scott L Pomeroy,Stuart H Orkin,Charles W M Roberts

DOI: https://doi.org/10.1016/j.ccr.2010.09.006

IF: 50.3

2010-01-01

Cancer Cell

Abstract:Epigenetic alterations have been increasingly implicated in oncogenesis. Analysis of Drosophila mutants suggests that Polycomb and SWI/SNF complexes can serve antagonistic developmental roles. However, the relevance of this relationship to human disease is unclear. Here, we have investigated functional relationships between these epigenetic regulators in oncogenic transformation. Mechanistically, we show that loss of the SNF5 tumor suppressor leads to elevated expression of the Polycomb gene EZH2 and that Polycomb targets are broadly H3K27-trimethylated and repressed in SNF5-deficient fibroblasts and cancers. Further, we show antagonism between SNF5 and EZH2 in the regulation of stem cell-associated programs and that Snf5 loss activates those programs. Finally, using conditional mouse models, we show that inactivation of Ezh2 blocks tumor formation driven by Snf5 loss.
Abstract 4799: Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes During Oncogenic Transformation

Barbara G. Wilson,Xiaohua Shen,Elizabeth S. McKenna,Xi Wang,Yoon‐Jae Cho,Edward C. Koellhoffer,Phuong Nguyen,Scott L. Pomeroy,Stuart H. Orkin,Charles W.M. Roberts

DOI: https://doi.org/10.1158/1538-7445.am10-4799

IF: 11.2

2010-01-01

Cancer Research

Abstract:Epigenetic alterations serve critical roles in cell fate decisions and have increasingly been implicated in cancer formation. The Polycomb Group (PcG) protein EZH2 mediates epigenetic gene silencing, displays pro-oncogenic properties in cell lines and is frequently overexpressed in cancer. Conversely, loss of function mutations in the tumor suppressor gene SNF5, a core subunit of the SWI/SNF chromatin remodeling complex, occur in several types of aggressive human cancers. Intriguingly, analysis of homeotic mutants in Drosophila suggests that PcG and SWI/SNF can serve antagonistic roles in the epigenetic control of gene expression. Here we have investigated functional relationships between these epigenetic regulators in oncogenic transformation by examining the role of EZH2 in tumors driven by SNF5 loss. Notably, SNF5-mutant tumors, despite being highly aggressive, are diploid and genomically stable, making them an ideal model with which to elucidate epigenetic drivers of oncogenesis. We show that targeted inactivation of Snf5 leads to increased expression of Ezh2 and that EZH2 is upregulated in SNF5- deficient cancers. A key mechanism by which SNF5 loss promotes oncogenesis is via downregulation of the p16INK4a tumor suppressor. We show that inactivation of Ezh2 restores normal levels of p16INK4a to Snf5-deficient fibroblasts. We further show that reducing the levels of EZH2 in a human SNF5-deficient tumor cell line leads to increased levels of p16INK4a accompanied by slowed proliferation and cellular senescence. Most importantly, using conditional mouse models, we show that inactivation of EZH2 completely blocks tumor formation driven by SNF5 loss. Our results demonstrate an essential role for Ezh2 in oncogenic transformation in vivo and show that perturbing the epigenetic balance of gene expression mediated by EZH2 silencing and SWI/SNF activation can have a profound effect on tumor formation. Further, we establish that targeted inhibition of EZH2 in vivo can have potent anti-cancer effects. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4799.
Regeneration, stem cells, and the evolution of tumor suppression

B J Pearson,A Sánchez Alvarado

DOI: https://doi.org/10.1101/sqb.2008.73.045

Abstract:All multicellular organisms have requirements for tumor suppression to regulate cellular proliferation during either embryonic development or adult life. However, different organisms have vastly different requirements. Adult tumor suppression is probably not crucial to organisms possessing both short life spans and largely postmitotic soma. In contrast, animals with lifelong tissue turnover or those capable of regenerating body parts lost to injury must possess evolutionarily selected mechanisms to control rates of cell proliferation such that tissue homeostasis can be maintained or restored after injury. We hypothesize that these biological differences may help to explain why the lists of tumor suppressor genes in humans and Drosophila are largely nonoverlapping. Here, we address this disparity by examining the tumor suppressor gene content of two outgroups to the vertebrates and flies/nematodes: the freshwater planarian and the single-celled choanoflagellate. Both of these organisms have recently had their genomes sequenced, giving us a first glimpse of which known tumor suppressor genes have been maintained during evolution. In addition, we attempt to resolve which genes may have had ancestral tumor suppressor function and which may have acquired this function de novo.
Lack of apoptosis leads to cellular senescence and tumorigenesis in Drosophila epithelial cells

Juan Manuel Garcia-Arias,Noelia Pinal,Sara Cristobal-Vargas,Carlos Estella,Ginés Morata

DOI: https://doi.org/10.1038/s41420-023-01583-y

2023-08-03

Cell Death Discovery

Abstract:Programmed cell death (apoptosis) is a homeostasis program of animal tissues designed to remove cells that are unwanted or are damaged by physiological insults. To assess the functional role of apoptosis, we have studied the consequences of subjecting Drosophila epithelial cells defective in apoptosis to stress or genetic perturbations that normally cause massive cell death. We find that many of those cells acquire persistent activity of the JNK pathway, which drives them into senescent status, characterized by arrest of cell division, cell hypertrophy, Senescent Associated ß-gal activity (SA-ß-gal), reactive oxygen species (ROS) production, Senescent Associated Secretory Phenotype (SASP) and migratory behaviour. We have identified two classes of senescent cells in the wing disc: 1) those that localize to the appendage part of the disc, express the upd , wg and dpp signalling genes and generate tumour overgrowths, and 2) those located in the thoracic region do not express wg and dpp nor they induce tumour overgrowths. Whether to become tumorigenic or non-tumorigenic depends on the original identity of the cell prior to the transformation. We also find that the p53 gene contributes to senescence by enhancing the activity of JNK.

cell biology
Deterministic evolution and stringent selection during preneoplasia

Kasper Karlsson,Moritz J. Przybilla,Eran Kotler,Aziz Khan,Hang Xu,Kremena Karagyozova,Alexandra Sockell,Wing H. Wong,Katherine Liu,Amanda Mah,Yuan-Hung Lo,Bingxin Lu,Kathleen E. Houlahan,Zhicheng Ma,Carlos J. Suarez,Chris P. Barnes,Calvin J. Kuo,Christina Curtis

DOI: https://doi.org/10.1038/s41586-023-06102-8

IF: 64.8

2023-05-31

Nature

Abstract:Abstract The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention 1 . Here we model occult preneoplasia by biallelic inactivation of TP53 , a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive aneuploidy, including copy number alterations and structural variants prevalent in gastric cancers, with evident preferred orders. Longitudinal single-cell sequencing of TP53- deficient gastric organoids similarly indicates progression towards malignant transcriptional programmes. Moreover, high-throughput lineage tracing with expressed cellular barcodes demonstrates reproducible dynamics whereby initially rare subclones with shared transcriptional programmes repeatedly attain clonal dominance. This powerful platform for experimental evolution exposes stringent selection, clonal interference and a marked degree of phenotypic convergence in premalignant epithelial organoids. These data imply predictability in the earliest stages of tumorigenesis and show evolutionary constraints and barriers to malignant transformation, with implications for earlier detection and interception of aggressive, genome-instable tumours.

multidisciplinary sciences
Deterministic Evolution and Stringent Selection During Pre-Neoplasia

Kasper Karlsson,Moritz J. Przybilla,Eran Kotler,Aziz Khan,Hang Xu,Kremena Karagyozova,Alexandra Sockell,Wing H. Wong,Katherine Liu,Amanda Mah,Yuan-Hung Lo,Bingxin Lu,Kathleen E. Houlahan,Zhicheng Ma,Carlos J. Suarez,Chris P. Barnes,Calvin J. Kuo,Christina Curtis

DOI: https://doi.org/10.1038/s41586-023-06102-8

IF: 64.8

2023-01-01

Nature

Abstract:The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention 1 . Here we model occult preneoplasia by biallelic inactivation of TP53 , a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive aneuploidy, including copy number alterations and structural variants prevalent in gastric cancers, with evident preferred orders. Longitudinal single-cell sequencing of TP53- deficient gastric organoids similarly indicates progression towards malignant transcriptional programmes. Moreover, high-throughput lineage tracing with expressed cellular barcodes demonstrates reproducible dynamics whereby initially rare subclones with shared transcriptional programmes repeatedly attain clonal dominance. This powerful platform for experimental evolution exposes stringent selection, clonal interference and a marked degree of phenotypic convergence in premalignant epithelial organoids. These data imply predictability in the earliest stages of tumorigenesis and show evolutionary constraints and barriers to malignant transformation, with implications for earlier detection and interception of aggressive, genome-instable tumours.
and haploinsufficiency equip colonic epithelium for oncogenic transformation

Nefeli Skoufou-Papoutsaki,Sam Adler,Shenay Mehmed,Claire Tume,Cora Olpe,Edward Morrissey,Richard Kemp,Anne-Claire Girard,Elisa B Moutin,Chandra Sekhar Reddy Chilamakuri,Jodi L Miller,Cecilia Lindskog,Fabian Werle,Kate Marks,Francesca Perrone,Matthias Zilbauer,David S Tourigny,Douglas J Winton

DOI: https://doi.org/10.1101/2024.03.27.586939

2024-03-28

Abstract:Normal aged tissues are thought to exist as a patchwork of mutant clones. However, the relevance of driver mutations in normal tissue in terms of cancer initiation has not been well described. Here, we sought a quantitative understanding of how different cancer drivers achieve an age-related mutational footprint in the human colonic epithelium and to relate the clonal behaviours they generate to cancer risk. Metanalysis of contemporary multiregional sampling studies of colorectal tumours revealed many of the weak or moderate cancer drivers are trunk mutations present in the last common ancestor from which cancers arise. To study the processes by which such driver mutations could contribute to cancer predisposition, immunohistochemistry was used to detect PTEN, SMAD4 and ARID1A deficient clones in normal colon FFPE surgical resection samples (N=182 patients). Age-related changes in clone size and frequency identified positive biases in clone dynamics that acted to increase the mutational footprint for ARID1A and PTEN but not SMAD4. engineered monoallelic loss of and implicated specific altered downstream pathways and acquired pro-oncogenic cellular fates corresponding to haploinsufficiency for these genes. analysis confirmed enhanced proliferation in both PTEN and ARID1A deficient clones and creation of an immune exclusive microenvironment associated with ARID1A deficiency. The behaviours resulting from haploinsufficiency of and exemplify how priming of the tissue through somatic mosaicism could contribute alternative combinations of genetic events leading to transformation.

Cancer Biology
Rethinking cancer initiation: The role of large-scale mutational events

Amil Shah

DOI: https://doi.org/10.1002/gcc.23213

Abstract:Cancer initiation is revisited in light of recent discoveries in cancer pathogenesis. Of note is the detection of mutated cancer genes in benign conditions. More significantly, somatic clones, which harbor mutations in cancer genes, arise in normal tissues from early development through adulthood, but seldom do they transform into cancer. Further, clustered mutational events-kataegis, chromothripsis and chromoplexy-are widespread in cancer, generating point mutations and chromosomal rearrangements in a single cellular catastrophe. These observations are contrary to the prevailing somatic mutation theory, which states that a cancer is caused by the gradual accumulation of mutations over time. A different perspective is proposed within the framework of Waddington's epigenetic landscape wherein tumorigenesis is viewed primarily as a disruption of cell development. Cell types are defined by their specific gene-expression profiles, determined by the gene regulatory network, and can be regarded as attractor states of the network dynamics: they represent specific, self-stabilizing patterns of gene activities across the genome. However, large-scale mutational events reshape the landscape topology, creating abnormal "unphysiological" attractors. This is the crux of the process of initiation. Initiation primes the cell for conversion into a tumor phenotype by oncogenes and tumor suppressor genes, which drive cell proliferation and clonal diversification. This view of tumorigenesis calls for a different approach to therapy.
Oncogenic Pathways and Loss of the Rab11 GTPase Synergize To Alter Metabolism in Drosophila.

Yingchao Nie,Shiyan Yu,Qi Li,Niraj K Nirala,Alla Amcheslavsky,Yvonne J K Edwards,Patrick W Shum,Zhong Jiang,Wei Wang,Biliang Zhang,Nan Gao,Y Tony Ip

DOI: https://doi.org/10.1534/genetics.119.302137

IF: 4.402

2019-01-01

Genetics

Abstract:Colorectal cancer is a complex disease driven by well-established mutations such as APC and other yet to be identified pathways. The GTPase Rab11 regulates endosomal protein trafficking, and previously we showed that loss of Rab11 caused intestinal inflammation and hyperplasia in mice and flies. To test the idea that loss of Rab11 may promote cancer progression, we have analyzed archival human patient tissues and observed that 51 out of 70 colon cancer tissues had lower Rab11 protein staining. By using the Drosophila midgut model, we have found that loss of Rab11 can lead to three changes that may relate to cancer progression. First is the disruption of enterocyte polarity based on staining of the FERM domain protein Coracle. Second is an increased proliferation due to an increased expression of the JAK-STAT pathway ligand Upd3. Third is an increased expression of ImpL2, which is an IGFBP7 homolog and can suppress metabolism. Furthermore, loss of Rab11 can act synergistically with the oncoprotein RasV12 to regulate these cancer-related phenotypes.
REV1 is implicated in the development of carcinogen-induced lung cancer

Chad A Dumstorf,Suparna Mukhopadhyay,Elangovan Krishnan,Bodduluri Haribabu,W Glenn McGregor

DOI: https://doi.org/10.1158/1541-7786.MCR-08-0399

Abstract:The somatic mutation hypothesis of cancer predicts that reducing the frequency of mutations induced by carcinogens will reduce the incidence of cancer. To examine this, we developed an antimutator strategy based on the manipulation of the level of a protein required for mutagenic bypass of DNA damage induced by the ubiquitous carcinogen benzo[a]pyrene. The expression of this protein, REV1, was reduced in mouse cells using a vector encoding a gene-specific targeting ribozyme. In the latter cells, mutagenesis induced by the activated form of benzo[a]pyrene was reduced by >90%. To examine if REV1 transcripts could be lowered in vivo, the plasmid was complexed with polyethyleneimine, a nonviral cationic polymer, and delivered to the lung via aerosol. The endogenous REV1 transcript in the bronchial epithelium as determined by quantitative real-time PCR in laser capture microdissected cells was reduced by 60%. There was a significant decrease in the multiplicity of carcinogen-induced lung tumors from 6.4 to 3.7 tumors per mouse. Additionally, REV1 inhibition completely abolished tumor formation in 27% of the carcinogen-exposed mice. These data support the central role of the translesion synthesis pathway in the development of lung cancer. Further, the selective modulation of members of this pathway presents novel potential targets for cancer prevention. The somatic mutation hypothesis of cancer predicts that the frequency of cancers will also be reduced.
Targeted P16(Ink4a) Epimutation Causes Tumorigenesis and Reduces Survival in Mice

Da-Hai Yu,Robert A. Waterland,Pumin Zhang,Deborah Schady,Miao-Hsudh Chen,Yongtao Guan,Manasi Gadkari,Lanlan Shen

DOI: https://doi.org/10.1172/jci76507

IF: 19.456

2014-01-01

Journal of Clinical Investigation

Abstract:Cancer has long been viewed as a genetic disease; however, epigenetic silencing as the result of aberrant promoter DNA methylation is frequently associated with cancer development, suggesting an epigenetic component to the disease. Nonetheless, it has remained unclear whether an epimutation (an aberrant change in epigenetic regulation) can induce tumorigenesis. Here, we exploited a functionally validated cis-acting regulatory element and devised a strategy to induce developmentally regulated genomic targeting of DNA methylation. We used this system to target DNA methylation within the p16(Ink4a) promoter in mice in vivo. Engineered p16(Ink4a) promoter hypermethylation led to transcriptional suppression in somatic tissues during aging and increased the incidence of spontaneous cancers in these mice. Further, mice carrying a germline p16(Ink4a) mutation in one allele and a somatic epimutation in the other had accelerated tumor onset and substantially shortened tumor-free survival. Taken together, these results provide direct functional evidence that p16(Ink4a) epimutation drives tumor formation and malignant progression and validate a targeted methylation approach to epigenetic engineering.
pRb Inactivation in Mammary Cells Reveals Common Mechanisms for Tumor Initiation and Progression in Divergent Epithelia

Karl Simin,Hua Wu,Lucy Lu,Dan Pinkel,Donna Albertson,Robert D Cardiff,Terry Van Dyke

DOI: https://doi.org/10.1371/journal.pbio.0020022

IF: 9.8

2004-02-17

PLoS Biology

Abstract:Retinoblastoma 1 (pRb) and the related pocket proteins, retinoblastoma-like 1 (p107) and retinoblastoma-like 2 (p130) (pRb(f), collectively), play a pivotal role in regulating eukaryotic cell cycle progression, apoptosis, and terminal differentiation. While aberrations in the pRb-signaling pathway are common in human cancers, the consequence of pRb(f) loss in the mammary gland has not been directly assayed in vivo. We reported previously that inactivating these critical cell cycle regulators in divergent cell types, either brain epithelium or astrocytes, abrogates the cell cycle restriction point, leading to increased cell proliferation and apoptosis, and predisposing to cancer. Here we report that mouse mammary epithelium is similar in its requirements for pRb(f) function; Rb(f) inactivation by T(121), a fragment of SV40 T antigen that binds to and inactivates pRb(f) proteins, increases proliferation and apoptosis. Mammary adenocarcinomas form within 16 mo. Most apoptosis is regulated by p53, which has no impact on proliferation, and heterozygosity for a p53 null allele significantly shortens tumor latency. Most tumors in p53 heterozygous mice undergo loss of the wild-type p53 allele. We show that the mechanism of p53 loss of heterozygosity is not simply the consequence of Chromosome 11 aneuploidy and further that chromosomal instability subsequent to p53 loss is minimal. The mechanisms for pRb and p53 tumor suppression in the epithelia of two distinct tissues, mammary gland and brain, are indistinguishable. Further, this study has produced a highly penetrant breast cancer model based on aberrations commonly observed in the human disease.

biochemistry & molecular biology,biology

No mutation, tumour initiation

Transient loss of Polycomb components induces an epigenetic cancer fate

Loss of the Polycomb group gene polyhomeotic induces non-autonomous cell overproliferation.

Evidence of epigenetic oncogenesis: a turning point in cancer research

Tumours form without genetic mutations

Sustained inactivation of the Polycomb PRC1 complex induces DNA repair defects and genomic instability in epigenetic tumors

Evolution and genomic signatures of spontaneous somatic mutation in Drosophila intestinal stem cells

Abstract LB-237: Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes Duringoncogenic Transformation

Dysregulation of epigenetically induced cancers

Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes During Oncogenic Transformation

Abstract 4799: Epigenetic Antagonism Between Polycomb and SWI/SNF Complexes During Oncogenic Transformation

Regeneration, stem cells, and the evolution of tumor suppression

Lack of apoptosis leads to cellular senescence and tumorigenesis in Drosophila epithelial cells

Deterministic evolution and stringent selection during preneoplasia

Deterministic Evolution and Stringent Selection During Pre-Neoplasia

and haploinsufficiency equip colonic epithelium for oncogenic transformation

Rethinking cancer initiation: The role of large-scale mutational events

Oncogenic Pathways and Loss of the Rab11 GTPase Synergize To Alter Metabolism in Drosophila.

REV1 is implicated in the development of carcinogen-induced lung cancer

Targeted P16(Ink4a) Epimutation Causes Tumorigenesis and Reduces Survival in Mice

pRb Inactivation in Mammary Cells Reveals Common Mechanisms for Tumor Initiation and Progression in Divergent Epithelia